AI in Drug Discovery: Where Are the Results?
Despite initial promises, AI-designed drugs have yet to be approved, with many startups shutting down and venture capital investment declining.
Experts believed AI could revolutionize scientific research, particularly in speeding up the expensive! and time-consuming process of drug discovery.
- AI-designed drugs have made it to clinical trials, but none have been approved.
- Venture capital investment in AI-designed drugs has decreased significantly in recent years.
- Many startups focused on AI-designed drugs have shut down.
AI is everywhere these days, and though there’s debate about how useful it is, one area where experts think it could be game-changing is scientific research.
To discuss the challenges and future of AI in drug discovery, Host Ira Flatow is joined by Peter Coveney, who studies how chemistry discoveries can be accelerated with algorithms and computers.
Author's summary: AI-designed drugs face challenges despite initial promises.